Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- View the Talks
-
1. Genetics and management of inherited cancer predisposition 1
- Prof. Joshua Schiffman
-
2. Genetics and management of inherited cancer predisposition 2
- Prof. Joshua Schiffman
-
3. The cytogenetics of childhood acute leukemia
- Dr. Susana C. Raimondi
-
4. Chromosome translocations and cancer
- Prof. Felix Mitelman
-
5. Acute myeloid leukemia: genetics, prognosis and treatments
- Prof. Stephen Nimer
-
6. Genetic abnormalities in acute lymphoblastic leukemia
- Prof. Ching Hon Pui
-
7. Molecular genetics of non-Hodgkin lymphoma
- Prof. Jude Fitzgibbon
-
8. Genetics of breast and ovarian cancer
- Prof. Jeffrey Weitzel
-
9. The genetics and genomics of familial renal carcinoma
- Prof. Eamonn Maher
-
10. Genomics of lung cancer
- Prof. Ramaswamy Govindan
-
11. The genetics of glioblastoma
- Dr. Hai Yan
-
12. Genetics of tumor metastasis 1
- Prof. Robert Weinberg
-
13. Genetics of tumor metastasis 2
- Prof. Robert Weinberg
-
14. CML: genetic paradigm of targeted therapy 1
- Prof. Michael W. Deininger
-
15. CML: genetic paradigm of targeted therapy 2
- Prof. Michael W. Deininger
-
16. The non-coding RNA revolution in the cancer society
- Prof. George Calin
-
17. Role of molecular markers in guiding therapy in cancer
- Prof. Joe Duffy
-
18. Functional cancer genomics
- Prof. Roderick Beijersbergen
-
19. Pharmacogenomics in cancer therapy
- Prof. Sharon Marsh
Printable Handouts
Navigable Slide Index
- Introduction
- Cancers harbor many genetic alterations
- SQC lung cancer genomic characterization
- Lung SQCCs targetable pathway alterations
- Genotype-driven therapy of cancer
- Targeted agents: dramatic - short-lived responses
- Resistance mechanisms to targeted therapeutics
- Signaling networks and targeted cancer therapy
- Functional cancer genomics
- Functional cancer genomics: new cancer therapy
- RNAi as functional genomic screening tool
- Genome editing using CRISPR/CAS9
- Comparison of RNAi and CRIPSR/CAS9
- Repression and activation using CRISPR/dCAS9
- Large scale pooled screening approaches (1)
- Large scale pooled screening approaches (2)
- Pooled shRNA screening in vitro
- BRAF mutant colon cancers response to inhibitors
- PLX4032-BRAF mut CRC cell lines & melanomas
- WiDr cells shRNA droup out screen: method
- WiDr cells shRNA drop out screen: results
- WiDr cells shRNA drop out screen: EGFR
- Inhibition EGFR: vulnerablility to BRAF inhibition
- EGFR suppression and BRAF inhibition in CRC
- EGFR and BRAF (V600E) inhibitors synergize
- Pooled negative selection screen for AML targets
- Pooled shRNA screening in vivo
- In vivo screening: liver cancer sorafenib resistance
- Sorafenib, PH-797804, Skepinone-L
- Functional cancer genomics
Topics Covered
- Cancer Genomics
- molecular targeted therapies
- RNA interference- Genome editing CRIPSR/CAS9
- Pooled screening technology in vitro
- Pooled screening technology in vivo
- Feedback regulation
- Combination Therapies
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Beijersbergen, R. (2015, October 29). Functional cancer genomics [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/JFAY4051.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Roderick Beijersbergen has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Biochemistry
Transcript
Please wait while the transcript is being prepared...
0:00
Hello.
I am Roderick Beijersbergen
from the Netherlands
Cancer Institute in Amsterdam.
And I will be talking
to you today
about functional
cancer genomics.
0:10
In the past decade,
rapid progress in the ability
to analyze
full genomes of cancers
has pointed out
that individual tumors
may contain hundreds
and thousand of mutations
across the entire genome.
Some tumors, such as
colorectal cancer, lung cancer
and melanoma, have frequently
even up to a 100,000 mutations.
Although the majority
of these mutations
will not directly affect
the coding region of genes,
and thus, not lead
to abnormal proteins,
estimates are that
10 to 100 mutations expressed
in coding regions will
result in the expression
of mutant proteins
with aberrant functions.
These abnormal proteins
and the biological pathways
and mechanisms they control
play important roles
in the development of cancer
and response
to cancer therapies.
It's an enormous challenge
for oncology research to map
and understand the role of each
of these genetic alterations
for the diagnosis, prognosis
and treatment of cancer.
In addition to the large
numbers of mutations
found in different tumor types,
it has also become clear
that within one tumor type,
for example lung cancer,
different mutational spectra
can be found
in individual patients.
1:19
This slide shows significantly
mutated genes
in 178 tumors of one type,
in this example,
squamous cell lung cancer.
Although the frequency
of the mutations
of the tumor suppressor
gene TP53 is high,
with more than
80 percent mutation frequency,
for other genes, even though
they are significantly mutated,
this mutation rate
is much lower.
This indicates that among
different tumors,
different mutations exist,
even within one tumor type.
This heterogeneity
among different tumors,
even from the same tumor type,
complicates the interpretation
and use of
this genetic information
for the treatment of cancer.
However, more in-depth analysis
of all the pathways involved,
for example, in cell proliferation,
growth, and survival,
which can be
due to different mutations
within the same
phenotypic outcome
can highlight all the pathways
and provide potential
therapeutic targets
for this type of cancer.